Invesco

Since 1981, IPC and our predecessor firms have established a reputation for excellence in investing, backing industry-leading venture, buyout, and other private equity funds within fully discretionary comingled and separately managed accounts. IPC complements our partnership investments by deploying capital through direct investments into private companies. Over our 30+ year history, we have seen many market cycles and have demonstrated a strong track record of navigating the ever-changing marketplace. The IPC investment team is responsible for all aspects of the investment process, from deal sourcing and due diligence to investing and monitoring.
RB

Robert Bayer

VP and Senior Credit Analyst

Theresa Boyd

Partner

Cindy Chong

Senior Associate

CC

Chris Cleghorn

Associate Portfolio Manager

DE

Dyice Ellis-Beckham

MD

RH

Ruth Hughes-Guden

MD

Evan Jaysane-Darr

Managing Partner

DE

Daniel E. Kubiak

Senior Director and Portfolio Manager

TL

Tiffany Lee

VP

Kelvin Liu

Partner

CM

Chris Marx

MD

HR

Howard Reich

MD

WL

Wilbur Louis Ross

SVP

Michelle Seager

Senior Associate, Investments

PS

Phillip Shaw

General Partner and CIO

BM

Benjamin M. Utt

MD and Global Partner

Alan Weinfeld

Partner

JY

Justin Yagerman

Director, Commercial Strategies

108 past transactions

Xenon Pharmaceuticals

Private Equity Round in 2006
XENON® is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. We apply our expertise to predict which phenotypes are caused by single-gene defects. By identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. Given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases

Aumni

Series B in 2021
Aumni is the VC industry's first plug & play portfolio intelligence platform and the solution that top VC firms use for a competitive edge and operational efficiency. Aumni audits, analyzes, and visualizes the key data trapped in VC deal documents to augment venture investment teams with the tools for better strategic decisions and improved daily operations. An investor's legal, economic, and control interests fundamentally inform and influence every activity that an investor can take. Aumni extracts and utilizes hundreds of data points from the underlying deal documents to track critical insights such as key investment rights, portfolio performance, and emerging investment patterns. The Aumni platform is for forward-thinking venture investment teams that seek a solution to the challenges of unlocking and structuring the untapped expanse of data in their portfolio.

Psioxus Therapeutics

Series C in 2015
PsiOxus Therapeutics Limited, a biotechnology company, develops immune therapeutics in oncology. It develops a dual action anabolic catabolic transforming agent for the treatment of cancer cachexia and sarcopenia; a chimeric oncolytic vaccine for the systemic treatment of metastatic cancer; and a research phase program for delivering therapeutic antibodies directly into tumors. PsiOxus Therapeutics Limited was formerly known as Myotec Therapeutics, Ltd. and changed its name to PsiOxus Therapeutics Limited in December, 2010. The company was founded in 2006 and is based in Abingdon, United Kingdom.

GENBAND

Venture Round in 2005
GENBAND is a global supplier of IP gateways, session border controllers and FMC security solutions. These high-performance, high-security gateway solutions are at the center of fixed and mobile networks around the globe, evolving, securing and improving communications networks.

Mereo BioPharma Group plc

Private Equity Round in 2015
Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. Mereo BioPharma Group plc was founded in 2015 and is headquartered in London, the United Kingdom.

Extricity, Inc.

Venture Round in 2000
Extricity, Inc. was acquired by Inovis, Inc. Extricity, Inc. operates as a provider of business-to-business software products. Its software products allow companies to manage the internal and external sharing of information; and the execution of interactions among software applications and business partners over the Internet. The company was founded in 1996 and is based in Belmont, California.
Thin Film Electronics ASA designs, develops, and produces ultrathin energy storage solutions for wearable devices, connected sensors, and other applications. Its solid-state lithium battery technology enables it to produce rechargeable batteries with high energy densities and long product lifetimes. The company was founded in 2005 is headquartered in Oslo, Norway.

RedBlack Software, LLC

Acquisition in 2019
RedBlack Software, LLC provides technology solutions to investment advisors, wealth managers, broker dealers, and financial institutions. The company offers Rebalance Express, a software application for portfolio monitoring, rebalancing, and trading. Additionally, it provides tools for single and multiple accounts rebalancing, real-time pricing, tax lot management, portfolio and trade management, security and asset class model creation, cash management, and compliance and trade report generation. RedBlack Software, LLC was founded in 2006 and is based in Bedford, New Hampshire.

Centrify Corporation

Series C in 2007
Centrify redefines security from a legacy static perimeter-based approach to protecting millions of scattered connections in a boundaryless hybrid enterprise. As the only industry-recognized leader in both Privileged Identity Management and Identity-as-a-Service, Centrify provides a single platform to secure each user’s access to apps and infrastructure through the power of identity services. This is Next Dimension Security in the Age of Access. Centrify is enabling over 5,000 customers, including over half the Fortune 50, to defend their organizations. To learn more visit www.centrify.com. The Breach Stops Here.

Oxford Nanopore Technologies

Venture Round in 2011
Oxford Nanopore Technologies Limited develops and commercializes nanopore-based electronic systems for analysis of single molecules. The company offers MinION, a portable device for molecular analysis based on nanopore technology and is adaptable for the analysis of DNA, RNA, proteins, and small molecules; MinIT, an analysis and device control accessory for nanopore DNA sequencing; PromethION, a tablet-sized benchtop instrument that provides real-time data streaming; GridION system for molecular sensing applications; 109 cDNA Kits for its real-time and scalable sequencing technology that provides high throughput whilst generating complete sequences of full-length cDNA strands; and Flongle, a paradigm of smaller on-demand DNA or RNA sequencing tests with the potential to transform a range of applications where insights are required at low cost. Its devices are used in scientific research, personalized medicine, crop science, and security and defense applications. The company sells its products online. Oxford Nanopore Technologies Limited was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies Limited in May 2008. The company was incorporated in 2005 and is based in Oxford, United Kingdom with additional offices in the United Kingdom, the United States, China, Japan, Germany, France, India, and Singapore.

Generator Hostel

Private Equity Round in 2014
Generator Hostel provides owns and operates hostels that provide accommodations (shared to private) for travelers.

Xeros

Venture Round in 2013
Xeros Ltd. is a new company focused on the development of "virtually waterless" laundry cleaning. Harnessing over 30 years of research by Professor Stephen Burkinshaw and the University of Leeds, Xeros is the brand name for a patented polymer based cleaning that creates step change advantage in the cost and environmental impact of aqueous wash cleaning.

Sigmatel

Private Equity Round in 2000
Sigmatel is a semiconductor company that designs, develops, and markets proprietary, mixed-signal integrated circuits, or ICs. Their ICs incorporate significant analog circuitry for manipulating real world signals such as sound and light, as well as digital circuitry for processing data represented by a series of ones and zeroes.

Pine Labs

Venture Round in 2021
Pine Labs offers a merchant platform that includes technology and financial solutions for merchants. These solutions are aimed at helping merchants in increasing their revenue and reducing cost, complexity, and risk. The company connects financial institutions and consumer brands to enable merchants to deliver value to their retail customers. It powers offline and online last-mile retail transactions, provides customer insights for targeted sales, and offers financial solutions. The company’s cloud-based platform powers 3,50,000+ POS terminals across 3700 cities and towns in India and Malaysia. Over 1,00,000 merchants across sectors - electronics, food and beverage, fashion, airlines, and more, use Pine Labs’ solutions. 15 major banks, 7 financial institutions, and 100+ brands are a part of Pine Labs’ platform.

Capital

Series A in 2021
Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.

GeNeuro

Post in 2022
GeNeuro is a biotechnology company that develops therapeutic drugs for diseases associated with the expression of pathogenic proteins of the human endogenous retroviral origin. The company is primarily focused on nervous system diseases such as multiple sclerosis and schizophrenia. Its products include GNbAC1, a therapeutic monoclonal antibody for the treatment of multiple sclerosis. It also develops diagnostic tests to dose the multiple sclerosis-associated retrovirus-ENV proteins in patients.GeNeuro was founded in 2006 and is based in Plan-Les-Ouates, Switzerland.

Circassia

Series B in 2008
Circassia Group Plc, a specialty pharmaceutical company, focuses on the development and commercialization of respiratory products. It operates through three segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; Tudorza for the treatment of COPD; and Duaklir, a fixed-dose combination of the long-acting muscarinic antagonist aclidinium bromide and long-acting beta agonist formoterol fumarate, which is administered twice-daily through the breath actuated Pressair inhaler for the maintenance treatment of COPD. It is also developing LungFit, a portable ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air. The company markets its products directly to specialists in the United States, the United Kingdom, China, Italy, and Germany, as well as through a network of partners internationally. Circassia Group Plc has a collaboration agreement with AstraZeneca to promote Tudorza and Duaklir for COPD treatment; and the United States and Chinese commercial rights to LungFit. The company was formerly known as Circassia Pharmaceuticals plc and changed its name to Circassia Group Plc in May 2020. Circassia Group Plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.

Oxagen

Venture Round in 2000
Oxagen Limited, a biopharmaceutical company, develops and commercializes anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhinoconjunctivitis. Its drug programs target the CRTH2 receptor that initiates and maintains allergic conditions. The company develops a pipeline of small molecule drugs. It serves customers in the United Kingdom, Russia, CIS countries, and internationally. Oxagen Limited was incorporated in 1996 and is based in London, United Kingdom.

Swiggy

Venture Round in 2022
Swiggy provides a complete food ordering and delivery solution from the best neighborhood restaurants to the urban foodie. Swiggy aims to stand out by offering a more curated list of restaurants and services, not to mention its own in-house delivery fleet that pick up orders from restaurants and deliver it to the customers. It charges between 15-40 percent in commission to restaurants and for smaller orders, customers pay an additional delivery charge between 20 and 50 rupees depending on their city. Currently, Swiggy is in eight cities where it has more than 9,000 restaurants on its platform.

Circassia

Series D in 2011
Circassia Group Plc, a specialty pharmaceutical company, focuses on the development and commercialization of respiratory products. It operates through three segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; Tudorza for the treatment of COPD; and Duaklir, a fixed-dose combination of the long-acting muscarinic antagonist aclidinium bromide and long-acting beta agonist formoterol fumarate, which is administered twice-daily through the breath actuated Pressair inhaler for the maintenance treatment of COPD. It is also developing LungFit, a portable ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air. The company markets its products directly to specialists in the United States, the United Kingdom, China, Italy, and Germany, as well as through a network of partners internationally. Circassia Group Plc has a collaboration agreement with AstraZeneca to promote Tudorza and Duaklir for COPD treatment; and the United States and Chinese commercial rights to LungFit. The company was formerly known as Circassia Pharmaceuticals plc and changed its name to Circassia Group Plc in May 2020. Circassia Group Plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.
Godrej Properties brings the Godrej Group philosophy of innovation and excellence to the real estate industry. Each Godrej Properties development combines a 119-year legacy of excellence and trust with a commitment to cutting-edge design and technology. Godrej Properties is currently developing residential, commercial and township projects spread across 10.3 million square meters (111 million square feet) in 12 cities.

StarVOX

Series D in 2001
StarVox products are sold and serviced through major solution providers such as Hewlett Packard as a complete, factory-integrated IP telephony solution for service providers. The HP/StarVox Next Generation Telephony Solution combines StarVox software with HP's Open Call Multi Controller application platforms and Cisco Powered Network equipment, making it a carrier-grade, industry-standard solution that will allow a full range of value-added services and upgrades

GENBAND

Series D in 2001
GENBAND is a global supplier of IP gateways, session border controllers and FMC security solutions. These high-performance, high-security gateway solutions are at the center of fixed and mobile networks around the globe, evolving, securing and improving communications networks.

Abogen Biosciences

Series C in 2021
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Brii Biosciences

Series C in 2021
Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.

MYND Management, Inc.

Venture Round in 2021
How about the industry’s first mobile app that gives you up-to-the-minute performance data on the fly, for on-the-go control of your real estate investment, wherever you are. You’ll instantly know when rents are paid and have a snapshot of your profits whenever you like. You can also review maintenance requests and approve expenses as they happen, and get alerts about things like local market trends. This radical departure from property management also includes unparalleled service from the Mynd team, led by Doug Brien and Colin Wiel, who have your best interests at heart, at all times. We’re in San Francisco’s East Bay, so get on the waitlist today. You won’t believe what else we have in Mynd for rental property management.

DoubleTwist

Series D in 2000
In December 1999, Pangea Systems became DoubleTwist, Inc. - a new application service provider (ASP)/ Internet company devoted to empowering life scientists. The change reflects a new focus on this Internet portal. DoubleTwist.com integrates powerful tools and data behind automated research agents that retrieve and interpret data based on the user's scientific questions. The company's traditional data warehousing and mining software power the site, enabling life science research through an easy-to-use interface on the Web. DoubleTwist has established a talented and experienced development team of scientific and technical personnel dedicated to building software solutions that address the biological data management needs of life scientists. DoubleTwist's scientific team is comprised of leading experts in their respective fields of biochemistry, molecular biology, protein chemistry, bioinformatics, computer science and computational biology. They come to DoubleTwist from world-renowned institutions, including Stanford University, UCLA, UC Berkeley, UCSF, University of Pennsylvania, Sandoz Pharmaceutical, Onyx Pharmaceutical, Incyte, Molecular Simulations, Molecular Dynamics, Roche and Glaxo Wellcome. The company's software engineers have extensive experience in commercial-grade software systems, with particular expertise in relational database and object-oriented development. They come to DoubleTwist from some of the industry's most successful companies, including Apple, Oracle and IBM.

LipoScience

Series E in 2003
LipoScience is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 8 million NMR LipoProfile tests have been ordered.

Luminex Trading & Analytics

Venture Round in 2015
Focused on helping the IM community efficiently source block liquidity through transparent trading protocols.

Nubank

Series G in 2021
Nubank issues, administrate, processes, and transfers payments related to post-paid credit cards and equity investment in other entities. It serves clients in Brazil. The company launched its proprietary loyalty rewards program ("Nubank Rewards"), as well as a digital account ("NuConta") that is already used by more than 17 million people. In Cristina Junqueira, David Velez, and Edward Wible founded EO2 Solucoes de Pagamento on May 6, 2013 that became Nubank in on June 25, 2013. It has its headquarters in São Paulo in Brazil.

Cast Iron Systems

Series D in 2005
Cast Iron Systems, Inc., a software-as-a-service integration appliance vendor, provides integration appliances for large and midsize companies. The company offers iA3000, an application integration appliance that offers network computing solutions. It also provides preconfigured solutions for enterprise and on-demand applications that enable users to offer connectivity to specific applications, as well as packaged integration processes to integration scenarios; and integration solutions for SAP applications, and Oracle applications and databases. In addition, the company offers consulting, technical support, and education services. Cast Iron Systems, Inc. was formerly known as IronHide Corporation. The company was founded in 2001 and is based in Mountain View, California.

Endpoints News

Series B in 2001
EndPoints Inc. is a fabless semiconductor company that provides controller chips used in mass-market consumer products that capture and display video and still digital images across the internet and other networks. The company’s products control the operation of inexpensive digital video and still cameras that can connect to the Internet. These controller chips process and communicate the images that are captured and digitized by CMOS image sensor chips and are then sent through one of the company’s interfaces (USB, 1394, Ethernet, etc.) to a PC.

POINT Biomedical

Private Equity Round in 2008
POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphereâ„¢. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphereâ„¢, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques

Spin Memory

Series A in 2012
Spin Transfer Technologies, Inc. was established by Allied Minds and New York University to develop and commercialize its orthogonal spin transfer magnetoresistive random access memory technology, OST-MRAM. The technology, discovered by Professor Andrew Kent, has enormous implications for the development of spin transfer MRAM devices, including faster switching times, lower power operation and scalability to smaller dimensions.

Aspect Medical Systems

Venture Round in 1997
Aspect Medical Systems develop technology that could measure a then unknown element of patient status – the direct effect of drugs and disease on the brain. Today, Aspect is recognized as a pioneer and global market leader in brain monitoring, having led the way to develop proprietary technologies that directly measure these effects and ultimately improve the quality and cost effectiveness of patient care.

Grab

Series H in 2019
Grab operates a mobile technology platform that integrates city transportation for driver-partners and customers in South East Asia. It offers services like GrabTaxi, GrabCar, GrabHitch, GrabShare, GrabCoach, GrabShuttle, GrabShuttle Plus, GrabFamily, JustGrab, GrabNow, and GrabRental. Grab offers services in Singapore, Indonesia, Philippines, Malaysia, Thailand, Vietnam, and Myanmar. Anthony Tan and Tan Hooi Lng founded it in 2012 and is headquartered in Singapore. It has additional offices in Seattle, Beijing, Bangalore, Jakarta, and Vietnam.

NovaSys

Venture Round in 2008
At NovaSys Health they value your participation as a contracted provider. Roughly 11,000 providers in this region and over 4,300 providers in Arkansas have contracted with NovaSys Health making it one of the largest health plans in Arkansas. They take pride in the relationships that they have cultivated with providers.

Circassia

Series C in 2009
Circassia Group Plc, a specialty pharmaceutical company, focuses on the development and commercialization of respiratory products. It operates through three segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; Tudorza for the treatment of COPD; and Duaklir, a fixed-dose combination of the long-acting muscarinic antagonist aclidinium bromide and long-acting beta agonist formoterol fumarate, which is administered twice-daily through the breath actuated Pressair inhaler for the maintenance treatment of COPD. It is also developing LungFit, a portable ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air. The company markets its products directly to specialists in the United States, the United Kingdom, China, Italy, and Germany, as well as through a network of partners internationally. Circassia Group Plc has a collaboration agreement with AstraZeneca to promote Tudorza and Duaklir for COPD treatment; and the United States and Chinese commercial rights to LungFit. The company was formerly known as Circassia Pharmaceuticals plc and changed its name to Circassia Group Plc in May 2020. Circassia Group Plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.

Confluent Photonics

Series B in 2003
Confluent Photonics Corporation is developing passive and active DWDM optical components for the telecommunications industry based on silicon-on-insulator (SOI) semiconductor fabrication techniques. The use of SOI along with the CMOS fabrication infrastructure developed to process SOI enables cost-effective high volume optical telecom component solutions for the access, metropolitan and long haul telecom markets. The compatibility of Confluent optical designs and manufacturing techniques with CMOS fabrication also provides a pathway for the future integration of optics and electronics on the same telecommunications chip. Current optical telecommunication product technologies and designs result in miniaturized optical lab benches lacking thermal and mechanical robustness. In contrast, Confluent is designing and fabricating Telcordia-compliant optical chip components for the automated manufacture of integrated optical circuits. These components are designed to be insensitive to their environment. Using semiconductor-manufacturing techniques provides built in optical alignment, high volume production and low cost.

Ishoni Networks

Series B in 2000
Ishoni Networks develops broadband engines for residential and business customers.
Glide Pharmaceutical Technologies is a clinical stage development company that focuses on solid dose formulations of therapeutics and vaccines. The company develops SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. Glide Pharmaceutical Technologies was formerly known as Caretek Medical.

Barosense

Series C in 2007
BaroSense is committed to develop and commercialize novel anti-obesity products that provide a meaningful contribution to this leading healthcare problem facing the United States today. BaroSense was conceived in order to create a safe, simple, effective, and minimally invasive alternative to the surgical treatment of obesity - an innovative approach to assist those people who need help beyond traditional diets, and who wish to avoid extensive, irreversible surgery.

Psioxus Therapeutics

Series B in 2012
PsiOxus Therapeutics Limited, a biotechnology company, develops immune therapeutics in oncology. It develops a dual action anabolic catabolic transforming agent for the treatment of cancer cachexia and sarcopenia; a chimeric oncolytic vaccine for the systemic treatment of metastatic cancer; and a research phase program for delivering therapeutic antibodies directly into tumors. PsiOxus Therapeutics Limited was formerly known as Myotec Therapeutics, Ltd. and changed its name to PsiOxus Therapeutics Limited in December, 2010. The company was founded in 2006 and is based in Abingdon, United Kingdom.
SciFluor Life Sciences is an Allied Minds funded company with a late-stage fluorination technology that improves drug properties such as metabolic stability, potency, bioavailability, and blood-brain-barrier penetration. The company's late-stage fluorination technology is licensed exclusively from Harvard University. SciFluor's technology enables end-stage or any-stage fluorination of a wide variety of organic compounds.
Chelsio is a technology company focused on solving high performance networking and storage challenges for virtualized enterprise data centers, cloud service installations, and cluster computing environments. Now shipping its fourth generation protocol acceleration technology, Chelsio is delivering hardware and software solutions including Unified Wire Ethernet network adapter cards, unified storage software, high performance storage gateways, unified management software, bypass cards, and other solutions focused on specialized applications. Chelsio is a privately-held subsystems company headquartered in Sunnyvale, California.

Cortina Systems

Series D in 2006
Cortina Systems is a leading supplier of intelligent communication solutions through continuous innovations in advanced port processing and connectivity to the Core, Metro, Access, and Enterprise Market Segments. With our state-of-the-art high-speed analogdigital integration, we deliver a wide suite of products that address our customers' performance, density, and flexibility needs enabling faster time-to-market, longer time-in-market, and increased revenue opportunities. Working closely with our customers to understand their system requirements and anticipate their needs, we are creating the foundation ingredients for new generations of services.

Calient Technologies

Series C in 2001
Calient provides high-density 3D MEMS (Micro-Electro-Mechanical Systems) optical circuit switching for software-defined networks and data centers. Its optical circuit switching technology is used by service providers, cloud computing, content delivery, and government networks. This offers businesses with adaptive photonic switching systems that enable dynamic optical layer optimization in software-defined networks and data centers. The company’s 3D-MEMS switches enable dynamic optical-layer sharing, optimization, and automation of high-performance test, compute, and network resources in data centers, optical transport networks, and DevOps test automation facilities. Calient Technologies was established in 1999 and is headquartered in Goleta, California.

Endgate

Venture Round in 2000
A leading supplier of RF subsystems for millimeterwave, broadband wireless access systems. Their products are used in point-to-point, point-to-multipoint, cellular backhaul and wireless fiber systems and are provided at various levels of integration depending upon the customers' needs. They include amplifiers, frequency converters and multiplers, antennas, integrated transceivers, and complete outdoor units. Their patented multi-chip integrated circuit (MCIC) or "flip chip" technology enables Endwave to design circuits that use smaller amounts of GaAs, have fewer bond wires that require manual tuning, and are well suited for high volume automated assembly. Endwave headquarters are in Sunnyvale, CA. with additional manufacturing facilities in Santa Clara and Diamond Springs.

NEXEON Limited

Series C in 2011
NEXEON Limited operates as a battery materials and licensing company that develops silicon anodes for lithium-ion batteries. It offers silicon anode technology solutions for various applications, including consumer electronic, electronic vehicle, sustainable energy, aerospace, medical, and defense industries in the United Kingdom and internationally. The company was founded in 2006 and is based in Abingdon, United Kingdom with an additional office in Yokohama, Japan.

Celoxica

Venture Round in 2007
Based in London, United Kingdom, Celoxica delivers latency market data access and order execution solutions to the advanced trading community. The company’s solutions include a full range of market data feed handlers for the main U.S. and European equities, options, futures exchanges, and FX. With clients that include trading firms who co-locate their strategic applications in high frequency trading environments, market making, liquidity provision, algorithmic trading, and smart order routing, the company also offers a single access point for brokers and their clients by handling inbound FIX, credit check, and outbound native protocol to the execution venues. Celoxica was founded in 1996.

ConSentry Networks

Series D in 2006
ConSentry Networks is leading the delivery of intelligent control. Customers around the globe have adopted their intelligent control, enabling them to capitalize on today's new business practices including using contractors, outsourcing and offshoring, and more rapidly establishing working partnerships. ConSentry Networks, Inc. was founded in 2003 and is based in Milpitas, California. The company has received funding from Accel Partners, DAG Ventures, INVESCO Private Capital, and Translink Capital.

VIEO

Series B in 2003
VIEO provides innovative application service level management solutions for ensuring business certainty. These solutions provide end-to-end visibility of Microsoft web-based and Citrix-based application infrastructures and pinpoint resource problems that impact service levels. Using VIEO solutions, IT organizations can improve service delivery while reducing costs and complexity. VIEO's awards include Computerworld's 2004 Innovative Technology Award and InfoWorld's 2004 Systems Management Product of the Year. Led by IT visionary and successful serial entrepreneur Bob Fabbio, VIEO is headquartered in Austin, Texas.

Cell Medica

Venture Round in 2012
Cell Medica is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease. Based on a number of academic studies, there is strong evidence that cellular immunotherapy can be used in a safe and effective manner to treat diseases ranging from infections to cancer. Cell Medica is both an R&D company developing new forms of cell therapies and a cell production/processing company providing clinical-grade cell formulations to hospitals for the treatment of patients.

SkyPilot Networks

Series B in 2001
Provider of carrier-class broadband wireless equipment and networking, wireless voip and other wireless applications

ConSentry Networks

Venture Round in 2009
ConSentry Networks is leading the delivery of intelligent control. Customers around the globe have adopted their intelligent control, enabling them to capitalize on today's new business practices including using contractors, outsourcing and offshoring, and more rapidly establishing working partnerships. ConSentry Networks, Inc. was founded in 2003 and is based in Milpitas, California. The company has received funding from Accel Partners, DAG Ventures, INVESCO Private Capital, and Translink Capital.

Cast Iron Systems

Series F in 2007
Cast Iron Systems, Inc., a software-as-a-service integration appliance vendor, provides integration appliances for large and midsize companies. The company offers iA3000, an application integration appliance that offers network computing solutions. It also provides preconfigured solutions for enterprise and on-demand applications that enable users to offer connectivity to specific applications, as well as packaged integration processes to integration scenarios; and integration solutions for SAP applications, and Oracle applications and databases. In addition, the company offers consulting, technical support, and education services. Cast Iron Systems, Inc. was formerly known as IronHide Corporation. The company was founded in 2001 and is based in Mountain View, California.

LogLogic

Series D in 2009
LogLogic is the provider of industry's only scalable log and security intelligence platform for the enterprise and cloud. LogLogic, with over 1300 customers, provides solutions that allow customers to collect and analyze terabytes of big data generated by their IT assets and gives Security, IT Ops, and Compliance professionals actionable information at their finger tips to identify issues proactively and make insightful decisions, and also get compliant with various regulations. Currently, LogLogic customers are leveraging its solutions to manage over 1,000 Petabytes (or 1 Exabyte) of data.

Expert System

Post in 2020
Expert System provides technology and tools that support the creation, development, implementation and management of AI applications to unlock the value of language in the enterprise at speed and scale. Its flagship platform provides a mix of natural language understanding and machine learning algorithms to help organizations bring humanlike comprehension of any kind of text to accelerate business processes, enhance knowledge discovery and improve decision making. Headquartered in Italy, the company operates throughout Europe, the Americas, Canada and the Middle East across a vast range of sectors and use cases including content enrichment, customer care, compliance, third party risk mitigation and intelligence applications.

Alkermes

Post in 2014
Alkermes Pharmaceutical Manufacturing and Global Biopharmaceutical Company

Lamellar Biomedical

Series C in 2017
Lamellar Biomedical Ltd. operates as a biotechnology company that develops and commercializes a range of medical devices and pharmaceuticals based on mimetics of extra-alveolar lamellar bodies. The company offers Lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. Its products target radiotherapy induced xerostomia, dry eye disease, cystic fibrosis, and infection. Lamellar Biomedical Ltd. was formerly known as Macrocom (964) Limited and changed its name to Lamellar Biomedical Ltd. in February 2007. The company was incorporated in 2006 and is based in Bellshill, United Kingdom.

Ishoni Networks

Series C in 2001
Ishoni Networks develops broadband engines for residential and business customers.

Touchdown Technologies

Series B in 2005
Touchdown Technologies, Inc. designs, manufactures, and supports MEMS probecards. The company offers ACCU-TORQ probe, a torsional contactor; and GIGA-TORQ probecards for DRAM applications. Its products support the production wafer test needs of semiconductor manufacturers. Touchdown Technologies, Inc. was formerly known as Integrated Micromachines, Inc. The company was founded in 2003 and is based in Baldwin Park, California.

Oxford Immunotec

Venture Round in 2012
Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company's first product is a TB test that diagnoses latent TB infection ( LTBI ) and TB disease. T-SPOT®.TB is an interferon gamma release assay ( IGRA ) which are designed to replace the century old Mantoux skin test ( TST ).

NOVASYS MEDICAL

Series D in 2008
$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Netcentives

Private Equity Round in 1999
On December 21, 2004, Netcentives, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Netcentives, Inc. provides loyalty and direct marketing solutions. It delivers a suite of programs for relationship marketing technologies and services for its Global 2000 client base. These programs include consumer, employee, and business loyalty solutions; customized e-mail marketing; and consulting services. The loyalty solutions enhance the economic value of customer, employee, and business relationships through large-scale custom programs, employee/partner recognition systems, and merchant-based programs. The company's direct marketing business uses customized, targeted e-mail to help its customers increase response rates and enhance the value of their membership base. The consulting services include strategy, design, and launch services, which enable customers to move from business concepts to successful programs and solutions. Netcentives also offers technology platforms and software applications for the management of online loyalty and direct marketing applications. In October 2001, the company filed a voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code together with its subsidiaries, Post Communications, Inc. and MaxMiles, Inc. The company is based in San Francisco, California.

SkyPilot Networks

Series C in 2005
Provider of carrier-class broadband wireless equipment and networking, wireless voip and other wireless applications

Antenova

Venture Round in 2007
Antenova, Ltd. engages in the design, development, and supply of standard and custom antennas, and radio frequency antenna modules. Its products are used in mobile handsets, adapters, portable devices, laptop computers, and wireless devices. Antenova, Ltd. was incorporated in 1999 and is headquartered in Stow-cum-Quy, the United Kingdom. It has design, and sales and support centers in Taipei, Taiwan; Chicago, Illinois; and Shanghai, China, as well as manufacturing operations in Taiwan and China.

OppenheimerFunds

Acquisition in 2018
They are dedicated to serving the needs of our clients, who range from financial advisors and individual investors to corporations and endowments.

ConSentry Networks

Series C in 2005
ConSentry Networks is leading the delivery of intelligent control. Customers around the globe have adopted their intelligent control, enabling them to capitalize on today's new business practices including using contractors, outsourcing and offshoring, and more rapidly establishing working partnerships. ConSentry Networks, Inc. was founded in 2003 and is based in Milpitas, California. The company has received funding from Accel Partners, DAG Ventures, INVESCO Private Capital, and Translink Capital.

AccessLine Communications

Venture Round in 2000
AccessLine Communications offers its users with hosted communications and voice services that gives customers and partners the freedom to focus on their businesses. It is a one-stop shop for cloud business applications that integrates the essential IT services which businesses need such as email, voice, file syncing and sharing, conferencing, instant messaging, identity and access management, mobility, security, and archiving. It offers special industry solutions such as construction, financial services, healthcare, high tech, legal, and manufacturing services. AccessLine Communications was founded in 1983 and it is located in the United States. The company was acquired by Telanetix on September 18, 2007.
Oxford Nanopore Technologies Limited develops and commercializes nanopore-based electronic systems for analysis of single molecules. The company offers MinION, a portable device for molecular analysis based on nanopore technology and is adaptable for the analysis of DNA, RNA, proteins, and small molecules; MinIT, an analysis and device control accessory for nanopore DNA sequencing; PromethION, a tablet-sized benchtop instrument that provides real-time data streaming; GridION system for molecular sensing applications; 109 cDNA Kits for its real-time and scalable sequencing technology that provides high throughput whilst generating complete sequences of full-length cDNA strands; and Flongle, a paradigm of smaller on-demand DNA or RNA sequencing tests with the potential to transform a range of applications where insights are required at low cost. Its devices are used in scientific research, personalized medicine, crop science, and security and defense applications. The company sells its products online. Oxford Nanopore Technologies Limited was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies Limited in May 2008. The company was incorporated in 2005 and is based in Oxford, United Kingdom with additional offices in the United Kingdom, the United States, China, Japan, Germany, France, India, and Singapore.

Arcot Systems

Series A in 2005
Arcot Systems, Inc. offers authentication and digital signing solutions to protect and verify digital identity. The company offers TransFort for Issuers that enables authentication for card holders and merchants; TransFort for Merchants, which enables authentication of cardholders that enroll in 3-D secure; RiskFort that blocks fraud in real-time; WebFort and ArcotID software-only authentication solutions; A-OK On-Demand that provides security for authentication process; and SignFort, which enables organizations to replace ‘print and sign’ methods with streamlined process for signing and approving documents. The company provides solutions for consumer portal protection, FFIEC compliance, identity management, Internet threat protection, SAFE biopharmaceutical compliance, and VPN authentication. It helps financial institutions, pharmaceutical companies, and e-shopping sites to prevent online fraud and identity theft. The company was founded in 1997 and is headquartered in Sunnyvale, California with a technology center in Bangalore, India.

NEXEON Limited

Private Equity Round in 2016
NEXEON Limited operates as a battery materials and licensing company that develops silicon anodes for lithium-ion batteries. It offers silicon anode technology solutions for various applications, including consumer electronic, electronic vehicle, sustainable energy, aerospace, medical, and defense industries in the United Kingdom and internationally. The company was founded in 2006 and is based in Abingdon, United Kingdom with an additional office in Yokohama, Japan.

LipoScience

Series F in 2006
LipoScience is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 8 million NMR LipoProfile tests have been ordered.

Barosense

Series D in 2009
BaroSense is committed to develop and commercialize novel anti-obesity products that provide a meaningful contribution to this leading healthcare problem facing the United States today. BaroSense was conceived in order to create a safe, simple, effective, and minimally invasive alternative to the surgical treatment of obesity - an innovative approach to assist those people who need help beyond traditional diets, and who wish to avoid extensive, irreversible surgery.

Cell Medica

Series B in 2014
Cell Medica is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease. Based on a number of academic studies, there is strong evidence that cellular immunotherapy can be used in a safe and effective manner to treat diseases ranging from infections to cancer. Cell Medica is both an R&D company developing new forms of cell therapies and a cell production/processing company providing clinical-grade cell formulations to hospitals for the treatment of patients.

Jemstep Inc.

Acquisition in 2016
Jemstep Inc. provides online investment guidance and management services for individual investors. It uses technology to provide ratings of mutual funds and ETFs. The company offers information on mutual funds, such as comparing funds, mutual fund ratings, mutual fund analysis, mutual fund performance, mutual fund screener, and mutual fund research; ETFs, which include investing in ETFs, and ETF research; and asset allocation, portfolio management, investment research, and investment analysis. Jemstep Inc. was founded in 2008 and is based in Los Altos, California.

PolyTherics

Venture Round in 2013
PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

IntelliFlo Ltd.

Acquisition in 2018
IntelliFlo Ltd has grown out of our desire to provide state of the art software that is keenly aligned with the business needs of our user base across the financial services sector. We are an IT software company but our focus on software as a service means our approach is rooted in best practice and delivering solutions from which you can derive real business value, as well as future proofing your operations in ever changing and challenging markets. Formed in 2004, we are based in Kingston-upon-Thames. Our delivery is based on technical knowledge and experience. As well as specialising in developing our web-based software solutions our team of dedicated IT and business professionals use their collective expertise across many different markets to provide effective solutions to meet a wide spectrum of business needs.

infirst Healthcare

Series A in 2013
infirst Healthcare Ltd. develops cocoa-flavoured medicine for the treatment of cough and cold. The company was incorporated in 2012 and is based in London, United Kingdom.

Hello Alfred

Series B in 2018
Named one of the 50 Most Innovative Companies in the World by Fast Company in 2018, Hello Alfred is quickly establishing itself as one of the most disruptive commerce channels around, trusted to deliver services, goods and retail experiences past your door. With more than 1 million home visits to more than 40,000 households in residential buildings across eight cities — from New York, Boston, and Chicago to Los Angeles and San Francisco — they’re building the future of urban living. Hello Alfred was founded in 2014 by Marcela Sapone and Jessica Beck, and has is heaquartered in New York, New York, United States.

Gelesis, Inc.

Private Equity Round in 2015
Gelesis, Inc., a biotechnology company, develops therapies to treat the genesis of gastrointestinal (GI) related chronic diseases. It develops a mechanobiology technology platform to treat obesity and other chronic diseases related to the GI pathway. The company also provides PLENITY, an orally administered, non-stimulant, non-systemic aid to weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and chronic idiopathic constipation. Gelesis, Inc. was founded in 2006 and is based in Boston, Massachusetts.

WhereNet

Venture Round in 2005
WhereNet Corporation offers wireless solutions for tracking and managing enterprise assets. I WhereNet provides an integrated wireless infrastructure for real-time location, messaging, and telemetry applications, including WhereLAN, a cellular network of locating access points, transmit devices; WhereLAN LOS, a network of tag transmission receivers which perform locations calculations, database functions, and systems management; WhereTag III, a low-powered active radio frequency transmitters associated with an asset; WhereTag IV, an asset tag, which can be configured to match specific location application requirements; WhereCall, a wireless messaging system used for parts replenishment in industrial manufacturing; and WherePort, a magnetic exciter that extends the functionality of WhereTags. The company also offers Visibility Software Server, a set of software development tools for integrating WhereNet, customer, and third-party applications. The company was founded in 1997 and is headquartered in Santa Clara, California. As of January 25, 2007, WhereNet Corporation operates as a subsidiary of Zebra Technologies Corp.

Genomics PLC

Series A in 2014
Genomics PLC develops algorithms and software solutions that focus on cancer, microbes, and rare diseases. Its solutions allow governments and healthcare providers to transform healthcare provisions for their citizens and members; pharmaceutical and biotechnology clients to de-risk the drug development process; clinicians and doctors to improve diagnoses and treatment options; and research laboratories and genome analysts to process results accurately. The company was incorporated in 2014 and is based in Oxford, United Kingdom.

Cortina Systems

Series C in 2005
Cortina Systems is a leading supplier of intelligent communication solutions through continuous innovations in advanced port processing and connectivity to the Core, Metro, Access, and Enterprise Market Segments. With our state-of-the-art high-speed analogdigital integration, we deliver a wide suite of products that address our customers' performance, density, and flexibility needs enabling faster time-to-market, longer time-in-market, and increased revenue opportunities. Working closely with our customers to understand their system requirements and anticipate their needs, we are creating the foundation ingredients for new generations of services.

Lamellar Biomedical

Venture Round in 2015
Lamellar Biomedical Ltd. operates as a biotechnology company that develops and commercializes a range of medical devices and pharmaceuticals based on mimetics of extra-alveolar lamellar bodies. The company offers Lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. Its products target radiotherapy induced xerostomia, dry eye disease, cystic fibrosis, and infection. Lamellar Biomedical Ltd. was formerly known as Macrocom (964) Limited and changed its name to Lamellar Biomedical Ltd. in February 2007. The company was incorporated in 2006 and is based in Bellshill, United Kingdom.

SpaceX, Inc.

Venture Round in 2014
Space Exploration Technologies is a space-transportation startup company founded by Elon Musk. SpaceX designs, manufactures, and launches advanced rockets and spacecraft. SpaceX develops crew and cargo capsules, engines, cryogenic tank structures, avionics, equipment, guidance, and control software. The company is developing the partially reusable launch vehicles Falcon 1 and Falcon 9. Founded in 2002, Space Exploration Technologies is headquartered in Hawthorne, California.

Cast Iron Systems

Series E in 2006
Cast Iron Systems, Inc., a software-as-a-service integration appliance vendor, provides integration appliances for large and midsize companies. The company offers iA3000, an application integration appliance that offers network computing solutions. It also provides preconfigured solutions for enterprise and on-demand applications that enable users to offer connectivity to specific applications, as well as packaged integration processes to integration scenarios; and integration solutions for SAP applications, and Oracle applications and databases. In addition, the company offers consulting, technical support, and education services. Cast Iron Systems, Inc. was formerly known as IronHide Corporation. The company was founded in 2001 and is based in Mountain View, California.

Vedanta Biosciences

Venture Round in 2016
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily. It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Centrify Corporation

Series D in 2011
Centrify redefines security from a legacy static perimeter-based approach to protecting millions of scattered connections in a boundaryless hybrid enterprise. As the only industry-recognized leader in both Privileged Identity Management and Identity-as-a-Service, Centrify provides a single platform to secure each user’s access to apps and infrastructure through the power of identity services. This is Next Dimension Security in the Age of Access. Centrify is enabling over 5,000 customers, including over half the Fortune 50, to defend their organizations. To learn more visit www.centrify.com. The Breach Stops Here.

Psioxus Therapeutics

Series A in 2010
PsiOxus Therapeutics Limited, a biotechnology company, develops immune therapeutics in oncology. It develops a dual action anabolic catabolic transforming agent for the treatment of cancer cachexia and sarcopenia; a chimeric oncolytic vaccine for the systemic treatment of metastatic cancer; and a research phase program for delivering therapeutic antibodies directly into tumors. PsiOxus Therapeutics Limited was formerly known as Myotec Therapeutics, Ltd. and changed its name to PsiOxus Therapeutics Limited in December, 2010. The company was founded in 2006 and is based in Abingdon, United Kingdom.

Source ETF

Acquisition in 2017
Source is uniquely positioned to deliver highly liquid products that respond to the challenges and opportunities of the market They partner with some of the world’s largest investment houses and asset managers to create products that either offer exposure to new opportunities in the market or deliver existing strategies more effectively. They work together to ensure all of their products are efficient and transparent. On top of this, they work closely with some of the most well respected trading houses in Europe to ensure that their products are also priced as fairly as possible and are tradable throughout the day. Source is a global investment firm and one of the fastest growing European providers of exchange traded products (ETPs) By focusing on the ever-evolving needs of investors, they have grown assets under management to more than $19 billion (as at 30 July 2014) since their launch in April 2009, and during this time investors have traded more than $575 billion of Source’s products. They offer investors an efficient and transparent way to invest in equities, fixed income and commodities, as well as some alternative asset classes. Their ETPs are open-ended and domiciled in Dublin.

Confluent Photonics

Series A in 2001
Confluent Photonics Corporation is developing passive and active DWDM optical components for the telecommunications industry based on silicon-on-insulator (SOI) semiconductor fabrication techniques. The use of SOI along with the CMOS fabrication infrastructure developed to process SOI enables cost-effective high volume optical telecom component solutions for the access, metropolitan and long haul telecom markets. The compatibility of Confluent optical designs and manufacturing techniques with CMOS fabrication also provides a pathway for the future integration of optics and electronics on the same telecommunications chip. Current optical telecommunication product technologies and designs result in miniaturized optical lab benches lacking thermal and mechanical robustness. In contrast, Confluent is designing and fabricating Telcordia-compliant optical chip components for the automated manufacture of integrated optical circuits. These components are designed to be insensitive to their environment. Using semiconductor-manufacturing techniques provides built in optical alignment, high volume production and low cost.

2Wire

Series D in 2001
2Wire is a San Jose, Calif. provider of broadband service products for companies serving consumers.2Wire is dedicated to developing integrated solutions to deliver broadband service and content throughout the home or small office. Built upon the company's core expertise and continued innovation in software and hardware, 2Wire products enable home and small business users to fully leverage the benefits of broadband. In addition, 2Wire solutions offer service providers with a flexible platform to deliver and manage feature-rich Internet, telephony, entertainment, and other enhanced broadband application services

Celoxica

Venture Round in 2005
Based in London, United Kingdom, Celoxica delivers latency market data access and order execution solutions to the advanced trading community. The company’s solutions include a full range of market data feed handlers for the main U.S. and European equities, options, futures exchanges, and FX. With clients that include trading firms who co-locate their strategic applications in high frequency trading environments, market making, liquidity provision, algorithmic trading, and smart order routing, the company also offers a single access point for brokers and their clients by handling inbound FIX, credit check, and outbound native protocol to the execution venues. Celoxica was founded in 1996.

Centrify Corporation

Series B in 2005
Centrify redefines security from a legacy static perimeter-based approach to protecting millions of scattered connections in a boundaryless hybrid enterprise. As the only industry-recognized leader in both Privileged Identity Management and Identity-as-a-Service, Centrify provides a single platform to secure each user’s access to apps and infrastructure through the power of identity services. This is Next Dimension Security in the Age of Access. Centrify is enabling over 5,000 customers, including over half the Fortune 50, to defend their organizations. To learn more visit www.centrify.com. The Breach Stops Here.

Oxford Nanopore Technologies

Venture Round in 2012
Oxford Nanopore Technologies Limited develops and commercializes nanopore-based electronic systems for analysis of single molecules. The company offers MinION, a portable device for molecular analysis based on nanopore technology and is adaptable for the analysis of DNA, RNA, proteins, and small molecules; MinIT, an analysis and device control accessory for nanopore DNA sequencing; PromethION, a tablet-sized benchtop instrument that provides real-time data streaming; GridION system for molecular sensing applications; 109 cDNA Kits for its real-time and scalable sequencing technology that provides high throughput whilst generating complete sequences of full-length cDNA strands; and Flongle, a paradigm of smaller on-demand DNA or RNA sequencing tests with the potential to transform a range of applications where insights are required at low cost. Its devices are used in scientific research, personalized medicine, crop science, and security and defense applications. The company sells its products online. Oxford Nanopore Technologies Limited was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies Limited in May 2008. The company was incorporated in 2005 and is based in Oxford, United Kingdom with additional offices in the United Kingdom, the United States, China, Japan, Germany, France, India, and Singapore.
MaxWest Environmental Systems develops a system with a gasification and heat integration process that converts biosolids into energy.

Lamellar Biomedical

Series A in 2013
Lamellar Biomedical Ltd. operates as a biotechnology company that develops and commercializes a range of medical devices and pharmaceuticals based on mimetics of extra-alveolar lamellar bodies. The company offers Lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. Its products target radiotherapy induced xerostomia, dry eye disease, cystic fibrosis, and infection. Lamellar Biomedical Ltd. was formerly known as Macrocom (964) Limited and changed its name to Lamellar Biomedical Ltd. in February 2007. The company was incorporated in 2006 and is based in Bellshill, United Kingdom.
Chelsio is a technology company focused on solving high performance networking and storage challenges for virtualized enterprise data centers, cloud service installations, and cluster computing environments. Now shipping its fourth generation protocol acceleration technology, Chelsio is delivering hardware and software solutions including Unified Wire Ethernet network adapter cards, unified storage software, high performance storage gateways, unified management software, bypass cards, and other solutions focused on specialized applications. Chelsio is a privately-held subsystems company headquartered in Sunnyvale, California.
Glide Pharmaceutical Technologies is a clinical stage development company that focuses on solid dose formulations of therapeutics and vaccines. The company develops SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. Glide Pharmaceutical Technologies was formerly known as Caretek Medical.

Amber Networks

Series A in 1999
Provider of telecommunications technology that enables service providers to deploy communications services, including legacy services, over next-generation Optical Internet core. The company is introducing an infrastructure router, called an Aggregation Service Router, that concentrates thousands of traditional TDM, frame relay, ATM, and other service feeds - alongside native IP traffic - onto a services provider's core Optical Internet networks.

Clarksons

Post in 2019
Clarksons offers its diverse and growing client base an unrivalled range of shipbroking services, sector research, on-hand logistical support and full investment banking capabilities in all key shipping and offshore sectors.

AccountNow

Series C in 2007
AccountNow is a leading provider of prepaid card financial solutions for the 40 million US consumers who do not have established credit, credit cards, or traditional banking relationships. AccountNow’s money saving offers give consumers an alternative to "traditional" checking accounts and access to the financial and payment systems, including Visa prepaid cards, Pay Anyone Bill Payment and FDIC-insured deposits. AccountNow Prepaid Cards are issued by The Bancorp Bank or MetaBank pursuant to a license from Visa U.S.A. Inc. or MasterCard International Incorporated. Cards can be used everywhere Visa debit cards or Debit MasterCard is accepted. MasterCard is a registered trademark of MasterCard International Incorporated. The Bancorp Bank and MetaBank; Members FDIC.